• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 19
      After Voxelotor: Navigating a Turning Point in Sickle Cell Therapy | ASH News Daily | American Society of Hematology - 6 month(s) ago

      On September 25, 2024, a major chapter in sickle cell treatment came to an abrupt close. Voxelotor, granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2019, was celebrated as the first therapy to target the underlying pathophysiology of sickle cell disease (SCD). By stabilizing sickle hemoglobin in its oxygenated state, voxelotor reduced red cell sickling and its complications. The phase III HOPE trial, which showed a 44% hemoglobin response rate compared to placebo,

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        The unexpected withdrawal of #VOXELOTOR for sickle cell disease shocked everyone. 👉🏾MUST-READ interview w/ experts @DrAlexisThompsn @jstrous1 🚩attend Monday 1030am Room 33 convention center @ASH_hematology https://t.co/Sq4XsxYSID https://t.co/NxVrH74poj

    • Mashup Score: 8
      Charging Toward New Therapies in Hematologic Malignancies | ASH News Daily | American Society of Hematology - 6 month(s) ago

      Department of Haematology, Oxford University Hospitals, Oxford, U.K. Gimme fuel, gimme fire Gimme that which I desire As we gear up for the information-packed days of #ASH24, our mitochondria will be working overtime to fuel our minds to navigate the rapidly evolving clinical and scientific data — and our legs, for those inevitable sprints between distant sessions. The Scientific Workshop Mitochondria and Metabolism in Blood Cancer – From Discovery to Patients will showcase how energy-generating processes

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        🧨 ASH NEWS DAILY highlight: Read why @CKBrierley’s mitochondria are fully charged up 🔋🔋⚡️in her ASH NEWS DAILY preview 🔗https://t.co/vbTcougwgx @JuliPerezBot @ASH_hematology https://t.co/FAkfoUIlIG

    • Mashup Score: 2
      Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma - PubMed - 8 month(s) ago

      Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden f …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        @nihardesai7 Hey great question! Other than cast nephropathy as @VincentRK said, we only give #WEEKLY. See our pub showing SAME EFFICACY & LESS NEUROPATHY with weekly Bortezomib https://t.co/tGPRwAGqfn @MayoMyeloma https://t.co/R6Cx6yAgo2

    • Mashup Score: 20
      Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging - 10 month(s) ago

      The term monoclonal gammopathy of clinical significance (MGCS) refers to a group of symptomatic monoclonal gammopathies that do not meet the diagnostic criteria for malignant plasma cell disorders, such as multiple myeloma or Waldenström macroglobulinemia. These symptoms are attributable to the paraneoplastic effects of monoclonal immunoglobulins that occur through diverse mechanisms. The presence of symptoms distinguishes MGCS from monoclonal gammopathy of undetermined significance, which lacks significant symptomatic presentation. The presentations of MGCS are manifold, adding to the diagnostic challenge. Clinical suspicion is key for accurate and timely diagnosis. Radiologic imaging can provide pivotal information to guide the diagnosis. In this review, we discuss MGCS from a radiology perspective and highlight pertinent imaging features associated with the disorders.

      Source: www.mdpi.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        Do you know specific #radiologic🩻 #imaging features define #MGCS entities? ➡️🚨our #imaging #MGCS review takes an entirely unique perspective @frbaffour @VincentRK @myelomaMD @jmikhaelmd @IMFnurseMyeloma @HJChoMDPhD1 👉🏾https://t.co/R5nfLSjY8y https://t.co/McgP6M0pJx

    • Mashup Score: 25
      Check out Mayo Clinic's team fundraising page for Multiple Myeloma Research Foundation - 10 month(s) ago

      Please support Mayo Clinic and Dr. Joselle Cook at the MMRF Walk/Run: Twin Cities. We are excited to be a part of this event again, and hope you will join our team!

      Source: give.themmrf.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        We’re raising awareness for #MultipleMyeloma & supporting patients with #MM and their families @theMMRF @HJChoMDPhD1 @jmikhaelmd @VincentRK @NorthTxMSG @MayoMyeloma Join me at the annual Minneapolis MMRF WALK/Run 9/14/24 👉🏾https://t.co/IsxbjbqhzS https://t.co/ISumLqVHe2

    • Mashup Score: 28
      Racial disparities in multiple myeloma and access to stem cell transplantation - 11 month(s) ago

      Blood Cancer Journal – Racial disparities in multiple myeloma and access to stem cell transplantation

      Source: www.nature.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        A swift editorial of Ailawadhi et al’s article assessing variables impacting transplant for #MM among racial/ethnic groups & my take on the path forward ⁦@VincentRK⁩ ⁦@jmikhaelmd⁩ https://t.co/Z6mSXUMBn2

    • Mashup Score: 20
      International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma   - 1 year(s) ago

      The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024. 

      Source: www.myeloma.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        I am thrilled to mentor @OkontaIngrid in the 2024 IMF Medical Student Scholars for Health Equity in Myeloma program! Excited to guide future leaders in addressing myeloma disparities. https://t.co/ifXXKkGtuU #IMFMedScholar #IMFMPOWER #HealthEquity #MyelomaResearch @jmikhaelmd

    • Mashup Score: 20
      International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma   - 1 year(s) ago

      The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024. 

      Source: www.myeloma.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        I am thrilled to mentor @OkontaIngrid in the 2024 IMF Medical Student Scholars for Health Equity in Myeloma program! Excited to guide future leaders in addressing myeloma disparities. https://t.co/ifXXKkGtuU #IMFMedScholar #IMFMPOWER #HealthEquity #MyelomaResearch @jmikhaelmd

    • Mashup Score: 19
      Hitting Us With Your Best Shot: the Best of ASH Malignant 2023 | ASH News Daily | American Society of Hematology - 2 year(s) ago

      Division of Hematology, Mayo Clinic, Rochester, MN  Ten years ago, at the 55 th ASH Annual Meeting and Exposition in New Orleans, the headline was, “Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma” since, for the first time, patients with relapsed refractory lymphoma and B-cell acute lymphoblastic leukemia (ALL) were treated with CD19 chimeric antigen receptors (CARs). The “Best of ASH 2013” also proclaimed imetelstat as the newest disease modifying agent for myelofibrosis which reversed

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        #ASH23 Wrap-up: Highlights of the incredible science and practice changing clinical trials from this year’s ASH🚨Read the cliff notes of @ASH_hematology BEST OF ASH (Malignant). @DocsDock200 @HadidiSamer @AlkaliDr @n_gangat ➡️https://t.co/XKBhM146Go https://t.co/BlrtrR9lok

    • Mashup Score: 5
      Addressing the disparities: the approach to the African American patient with multiple myeloma - 2 year(s) ago

      Blood Cancer Journal – Addressing the disparities: the approach to the African American patient with multiple myeloma

      Source: www.nature.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	JoselleCookMD
        JoselleCookMD

        Really engaging and pertinent read. Congrats @CraigEmmittCole @DrBlueMD @jmikhaelmd ➡️ https://t.co/TMaL9JOfFG https://t.co/6UfO2WZ5BW

    Load More

    Joselle Cook

    @JoselleCookMD

    Second year Heme-Onc fellow @mayoclinic Rochester | Passionate for malignant heme |dyspro | myeloid |diversity&inclusion | adventurer

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings